Promising Alzheimer's drugs can slow progression when started early, but the infrastructure for population-scale screening does not yet exist.
Reporting in the Today Got Better brief
several promising Alzheimer's drugs have shown they can slow progression when started early, but the clinical infrastructure for population-scale screening does not exist yet